{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026664","form_type":"8-K/A","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.956567+00:00","generated_at":"2026-05-31T09:25:20.115039+00:00","sec_items":["9.01","2.02","7.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Contineum Q2 cash $218.7M; R&D $7.9M; IPO net $107.9M; Phase 2 enrollment on track","bullets":["Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at YE 2023.","R&D expenses $7.9M in Q2, down from $9.5M YoY, driven by lower consulting/manufacturing offset by Phase 2 costs.","G&A expenses $3.0M, up from $1.6M YoY on higher consulting and personnel costs.","IPO completed in April 2024 with net proceeds of $107.9M.","Enrollment ongoing in Phase 2 VISTA trial of PIPE-307 for RRMS; expects completion in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026664","json":"https://secwatch.observer/filing/0001437749-24-026664.json","markdown":"https://secwatch.observer/filing/0001437749-24-026664.md","text":"https://secwatch.observer/filing/0001437749-24-026664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924026664/0001437749-24-026664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774924026664/cont20240813_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:25:20.115039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}